Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | BCR | P11274 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | PRKCA | P17252 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TLR4 | O00206 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497826 | 0.85 | MEN1 (0.71) | MAPTKMT2AMEN1LMNAEGFR | |
| SCHEMBL13037068 | 0.82 | HPGD (0.66) | CYP11B1CYP11B2MAPTKMT2AMEN1 | |
| SCHEMBL5443862 | 0.80 | TLR4 (0.58) | MAPTKMT2AMEN1LMNAABL1 | |
| SCHEMBL5443864 | 0.80 | TLR4 (0.58) | MAPTKMT2AMEN1LMNAABL1 | |
| SCHEMBL12412918 | 0.79 | KMT2A (0.70) | CYP11B1CYP11B2MAPTKMT2AMEN1 | |
| SCHEMBL28393752 | 0.77 | RAB9A (0.75) | MAPTKMT2AMEN1LMNAEGFR | |
| SCHEMBL29618407 | 0.77 | NPC1 (0.51) | MAPTKMT2AABL1EGFRPRKCA | |
| SCHEMBL3950825 | 0.77 | NPC1 (0.51) | MAPTKMT2AABL1EGFRPRKCA | |
| SCHEMBL28395190 | 0.76 | MAPT (0.54) | MAPTKMT2AMEN1LMNAABL1 | |
| SCHEMBL28390980 | 0.75 | HDAC3 (0.53) | MAPTKMT2AMEN1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | CYP11B1 4261/4885CYP11B2 4444/4885MAPT 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.